Desmoplastic small round cell tumors (DSRCTs) are a rare and aggressive form of soft tissue sarcoma that predominantly affects adolescents and young adults. Characterised by the pathognomonic ...
Letetresgene autoleucel (lete-cel) showed a 42% response rate in a phase 2 trial for synovial sarcoma and myxoid/round cell liposarcoma. The trial included 64 patients, with 41% response in synovial ...
Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of analysis Interim analysis data reinforces the ...
Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials In this pilot study, we assessed the ...
Cell therapies first reached patients as treatments for blood cancers. Adaptimmune Therapeutics’ work in this therapeutic modality has culminated in an FDA nod in synovial sarcoma, a regulatory ...
Afami-cel, sold as Tecelra by Adaptimmune, is the first gene therapy to be approved for the rare form of cancer and the first FDA-approved T-cell receptor gene therapy. The accelerated approval was ...
Afamitresgene-autoleucel is an autologous T-cell immunotherapy designed to target cancer cells in solid tumors expressing melanoma-associated antigen A4. The Food and Drug Administration (FDA) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback